AGORACOM Small-cap Investor Relations Blog

Agoracom Blog

The Real Promise of LSD, MDMA and Mushrooms for Medical Science SPONSOR: MOTA Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca

Posted by AGORACOM at 11:47 AM on Monday, August 10th, 2020

SPONSOR: Mota Ventures Corp is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Mota is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here for More Info

Psychedelic science is making a comeback.

Scientific publications, therapeutic breakthroughs and cultural endorsements suggest that the historical reputation of psychedelics — such as lysergic acid diethylamide (LSD), mescaline (from the peyote cactus) and psilocybin (mushrooms) — as dangerous or inherently risky have unfairly overshadowed a more optimistic interpretation. Recent publications, like Michael Pollan’s How to Change your Mind, showcase the creative and potentially therapeutic benefits that psychedelics have to offer — for mental health challenges like depression and addiction, in palliative care settings and for personal development.

Erika Dyck

Major scientific journals have published articles showing evidence-based reasons for supporting research in psychedelic studies. These include evidence that pscilocybin significantly reduces anxiety in patients with life-threatening illnesses like cancer, that MDMA (3,4-methylenedioxy-methamphetaminecan; also known as ecstasy) improves outcomes for people suffering from PTSD and that psychedelics can produce sustained feelings of openness that are both therapeutic and personally enriching.

Other researchers are investigating the traditional uses of plant medicines, such as ayahuasca, and exploring the neurological and psychotherapeutic benefits of combining Indigenous knowledge with modern medicine.

I am a medical historian, exploring why we now think that psychedelics may have a valuable role to play in human psychology, and why over 50 years ago, during the heyday of psychedelic research, we rejected that hypothesis. What has changed? What did we miss before? Is this merely a flashback?

Healing trauma, anxiety, depression

In 1957, the word psychedelic officially entered the English lexicon, introduced by British-trained and Canadian-based psychiatrist Humphry Osmond.

Osmond studied mescaline from the peyote cactus, synthesized by German scientists in the 1930s, and LSD, a laboratory-produced substance created by Albert Hofmann at Sandoz in Switzerland. During the 1950s and into the 1960s, more than 1,000 scientific articles appeared as researchers around the world interrogated the potential of these psychedelics for healing addictions and trauma.

But, by the end of the 1960s, most legitimate psychedelic research ground to a halt. Some of the research had been deemed unethical, namely mind-control experiments conducted under the auspices of the CIA. Other researchers had been discredited for either unethical or self-aggrandizing use of psychedelics, or both.

Timothy Leary was perhaps the most notorious character in that regard. Having been dismissed from Harvard University, he launched a recreational career as a self-appointed apostle of psychedelic living.
Drug regulators struggled to balance a desire for scientific research with a growing appetite for recreational use, and some argued abuse, of psychedelics.

In the popular media, these drugs came to symbolize hedonism and violence. In the United States, the government sponsored films aimed at scaring viewers about the long-term and even deadly consequences of taking LSD. Scientists were hard-pressed to maintain their credibility as popular attitudes began to shift.

Now that interpretation is beginning to change.

https://news.usask.ca/articles/research/2018/the-real-promise-of-lsd,-mdma-and-mushrooms-for-medical-science.php

Tags: #Europe, #Psilocybin, #psychedelic, #Sales, Cannabis, CBD, CSE, EBITDA, FirstClassCBD
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on The Real Promise of LSD, MDMA and Mushrooms for Medical Science SPONSOR: MOTA Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca

Gold-Silver Ratio Reaches Its Highest Level In 87 Years From Its Lowest Level In 41 Years SPONSOR: Affinity Metals $AFF.ca $MKR.ca $SII.ca $TUD.ca $GTT.ca $AMK.ca $OSK.ca $RKR.ca

Posted by AGORACOM at 9:56 AM on Monday, August 10th, 2020

Affinity is focused on the acquisition, exploration and development of strategic metal deposits within North America. In addition to the West Timmins Gold project, Affinity is advancing the Regal Project in the northern end of the prolific Kootenay Arch. Regal hosts two major geophysical anomalies as well as three past producing mines. Recent drill results included a new silver discovery with an 11.10 meter interval of 143.29 g/t silver which included a 0.55 meter interval of 2,612.0 g/t silver Click Here For More Info

The gold-silver ratio indicates how many ounces of silver are required to buy one ounce of gold. In time periods where the ratio is relatively high, it acts as a leading indicator for a rise in silver’s value

As technical indicators go, the ratio of gold price to silver prices, commonly referred to as the gold-silver ratio, is considered by precious metal traders to be one of the most reliable indicators for forward price movements in silver.

The gold-silver ratio indicates how many ounces of silver are required to buy one ounce of gold. In time periods where the ratio is relatively high, it acts as a leading indicator for a rise in silver’s value.

Previously the highest the ratio has ever been was 132 to 1 in 1933, when the US government invoked Executive Order 6102 and forced US citizens to sell all but a small portion of their gold and silver holdings to the Federal Reserve.

In more recently the highest the ratio has reached id 97.3 to 1 in February 1991 (Figure 1), at the height of a global economic recession. After this high in the ratio, the silver price rose in a continued uptrend from an average price of US$3.74/oz in February 1991 to US$6.84/oz in February 1998, an increase of 83%.

Figure 1: Gold-Silver Ratio since 1990

Source: Mining and Metals Research Corporation Ltd.

In June 2003, after a sustained five-year period of lower gold-silver ratios, the gold-silver ratio reached a high of 78.7:1, over the next five years the silver price rose from US$4.53/oz to a high of US$19.32/oz in March 2008, (Figure 1) an increase of 326%.

A spike in the gold-silver ratio in December 2008 to 79.3:1, associated with another global recession, was a leading indicator of a 315% increase in the silver price from US$10.29/oz in December 2008 to US$42.7 in April 2011 (Figure 1).

The gold-silver ratio has now risen from a low of 34.7:1 in April 2011, its lowest level since 1979, to its highest level in 87 years of 111.7:1 in April 2020, before reducing to 90.6:1 in July on the back of a 35% rise in the silver price over just three months (Figure 1).

Could we now be facing a sustained uptrend in the silver price?

Historical precedent appears to suggests so, only once in history was silver more undervalued compared to gold than it was in April 2020 and that was in 1933 when the US Government forced its citizens to sell their precious metal holdings.

Source: https://www.proactiveinvestors.co.uk/companies/news/926237/gold-silver-ratio-reaches-its-highest-level-in-87-years-from-its-lowest-level-in-41-years-926237.html

Tags: #AffinityMetals, #BCMining, #Canada, #Discovery, #Drilling, #GoldStandard, #Incrementum, #InGoldWeTrust, #silver, #TaviCosta, AFF, AOTH_RMills, CrescatCapital, Melkior
Posted in Affinity Metals, All Recent Posts | Comments Off on Gold-Silver Ratio Reaches Its Highest Level In 87 Years From Its Lowest Level In 41 Years SPONSOR: Affinity Metals $AFF.ca $MKR.ca $SII.ca $TUD.ca $GTT.ca $AMK.ca $OSK.ca $RKR.ca

Kontrol’s $KNR.ca COVID-19 Technology Receives Initial Positive Lab Test Results $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 9:24 AM on Monday, August 10th, 2020

— Kontrol BioCloud® —

Announced that the detection mechanism of the Kontrol BioCloud® analyzer, has received initial positive lab results
Kontrol is developing a new technology designed to detect and alert for COVID-19 in real-time, through rapid on-site air sampling and detection of aerosol and droplet encapsulated viruses in indoor and outdoor environments
The next stage of testing will be with the live COVID-19 virus in a controlled environment and the BioCloud prototype operating in real-time
This part of the ongoing testing is anticipated to be completed in the next two to three weeks

TORONTO, ON / August 10, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that the detection mechanism of the Kontrol BioCloud® analyzer (“BioCloud“), has received initial positive lab results.

Can we measure for COVID-19 like we do for air quality?

Drawing from its extensive industry experience in air emissions and air quality monitoring, Kontrol is developing a new technology designed to detect and alert for COVID-19 in real-time, through rapid on-site air sampling and detection of aerosol and droplet encapsulated viruses in indoor and outdoor environments.

“We are pleased to announce that our detection mechanism, previously announced on August 5th, 2020, has completed its initial proof of concept test results. We have now validated that our detection mechanism can detect COVID-19 specific components in air samples under a controlled experiment,” says Paul Ghezzi, Chief Executive Officer of Kontrol. “The controlled testing was conducted by independent consultants, Dr. David Heinrichs, PhD (Heinrichs Laboratory), and Dr. Jimmy Dikeakos, PhD (Dikeakos Laboratory) – experts in the study of Microbiology and Immunology.”

Next Stage of Testing

The initial testing was designed to validate the function of the detection mechanism. The testing was limited to a controlled environment with the detection mechanism, and not the complete operation of the BioCloud analyzer.

The next stage of testing will be with the live COVID-19 virus in a controlled environment and the BioCloud prototype operating in real-time. This part of the ongoing testing is anticipated to be completed in the next two to three weeks. It is important to note that Kontrol is not making any representations about the operation of the BioCloud analyzer at this time. Following the testing of the BioCloud analyzer in real-time the lab results will be announced, and a final report will be prepared for the National Research Council of Canada for their review.

“As we continue testing, we have also started the process of establishing procurement and supply chain solutions for the potential production of the BioCloud and we remain in discussions with the National Research Council of Canada for their continued support,” says Gary Saunders, VP of Kontrol. “Given the urgency of creating safe spaces as the economy re-opens, we are working around the clock to move our technology forward and we appreciate the efforts of our team.”

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

Tags: COVID-19, CSE, energy conservation, google nest, green energy, smart building
Posted in Featured, Kontrol Energy Corp. | Comments Off on Kontrol’s $KNR.ca COVID-19 Technology Receives Initial Positive Lab Test Results $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Loop Insights $MTRX.ca Announces Reseller Partnership And First Sale With Vend, A Global POS Company Used In 25,000 Stores Across 140 Countries $QUIS.ca $MCLD.ca $NXO.ca

Posted by AGORACOM-JC at 7:09 AM on Monday, August 10th, 2020

Announced the signing of a channel reseller partnership with global cloud-based Point-of-Sale (POS) company, Vend, as well as, the first sale to a Vend client
Vend is the first POS built for iOS and is now used in over 25,000 stores across 140 countries. Vend’s fast growth and global reach creates opportunities across the world for Loop and its technology in the retail vertical.
First Implementation with Wild Bird Centers of America Inc. Franchise

VANCOUVER, BC, Aug. 10, 2020 – Loop Insights Inc. (TSXV: MTRX) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, automated marketing, and contact tracing to the brick and mortar space, is pleased to announce the signing of a channel reseller partnership with global cloud-based Point-of-Sale (POS) company, Vend, as well as, the first sale to a Vend client.

VEND UNLOCKS ACTIVE OPPORTUNITIES IN $5T GLOBAL RETAIL INDUSTRY

Vend is the first POS built for iOS and is now used in over 25,000 stores across 140 countries. Vend’s fast growth and global reach creates opportunities across the world for Loop and its technology in the retail vertical. To this end, the companies have already secured the first implementation at a Vend client, Wild Birds Centers of America Inc. – a North American aviary retail franchise with 30 stores – and subsidiary of Global Harvest Foods Ltd. Loop plans on widening the scope of opportunity Global Harvest Foods.

Furthermore, Vend is already in discussions with several other retail chains and both companies expect to announce additional implementations in the near future.

Loop Insights CEO, Rob Anson stated “This is a significant partnership for Loop given the fact both companies offer cloud-based services that provide a strong foundation for rapid scalability and growth. We are both driven to acquire multi-store clients to drive faster, larger adoption rates. As seen by our first implementation with Wild Bird Centers of America, VendHQ is already demonstrating huge value to Loop as a channel reseller. With active conversations already taking place with many of Vend’s global clients, our goals for global penetration into retail are already taking shape.”

Jake West, Director of Business Development at Vend stated “We are beyond excited to be partnering with Loop Insights to provide our retailers with robust, enterprise-level tools. With COVID 19, Vend has seen an increase in the number of mid-market and enterprise retailers that are moving to Vend to take advantage of modern, cloud-based technology. Loop Insights is a perfect complement to Vend’s platform, in that, collectively we are able to deliver enterprise & franchise reporting tools, deep product insights and even trends on consumer behavior to our retailers. Vend has long had a partner focused approach, where we partner with the best-of-breed companies like Loop to deliver our clients with an overall superior experience.

LOOP’S SOFTWARE INTEGRATION CREATES SCALABLE CHANNEL RESELLER OPPORTUNITIES

The addition of Loop’s API provides Vend clients the unique ability to connect transactional data across all physical retail locations and e-commerce platforms for single stores, multi-store franchises, and international enterprise retail customers. The companies will first integrate Loop’s powerful insights service at Wild Bird Centers of America—a franchise with 30 retail stores in Canada and the United States; Loop plans on widening the scope of opportunity to its umbrella company, Global Harvest Foods Ltd.

Without the need for hardware, Loop Cloud delivers a frictionless implementation process that allows for large-scale adoption and, ultimately, adds high margin revenue-generating power to Loop’s current Software as a Service(SaaS) revenuemodel. As a channel reseller for Loop’s technology, the companies anticipate revenue from onboarding fees and SaaS fees. Loop’s software API integration also supports seamless access to its other AI-driven services: automated personalized engagement and programmatic advertising. The addition of these services would increase the clients’ monthly SaaS fees, and add additional revenue for Loop through distribution/redemption of third-party promotions.

This Press Release Is Available On The Loop Insights Verified Forum On AGORACOM For Shareholder Discussion and Q&A https://agoracom.com/ir/LoopInsights/forums/discussion

About Vend: Vend is a cloud-based point-of-sale and retail management software that lets retailers run their business in-store, online, and on-the-go. Vend includes inventory management, Ecommerce integrations, customer loyalty, and reporting analytics tools. The first POS built for iOS, Vend is trusted by retailers in over 140 countries and is used in more than 25,000 stores worldwide. Vend integrates with leading tools like Bigcommerce, Quickbooks and Marsello and provides seamless integrated payment options by partnering with major banks and processors around the world. Founded in 2010, Vend has offices in Auckland, London, Toronto and Melbourne, and has raised more than $50 million from top-tier investors. For more information, please visit: https://www.vendhq.com/

About Loop Insights: Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia.

Forward-Looking Statements/Information:

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LOOP Website: www.loopinsights.ai

Facebook: @LoopInsights

Twitter: @LoopInsights

LinkedIn: @LoopInsights

SOURCE LOOP Insights Inc.

Tags: AI, covid19, Covid19 tracing, CSE, internet of things, IOT, tsx, tsx-v
Posted in Featured, Loop Insights Inc. | Comments Off on Loop Insights $MTRX.ca Announces Reseller Partnership And First Sale With Vend, A Global POS Company Used In 25,000 Stores Across 140 Countries $QUIS.ca $MCLD.ca $NXO.ca

Avicanna Inc. $AVCN.ca to Host Second Quarter 2020 Investor Conference Call $CRDL.ca $PCLO.ca $WEED.ca $ACB.ca

Posted by AGORACOM-JC at 6:46 PM on Friday, August 7th, 2020

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

TORONTO, Aug. 7, 2020 – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has scheduled a conference call on Monday, August 17, 2020 at 9:00AM Eastern Time to discuss the results for its fiscal second quarter ended June 30, 2020. Aras Azadian, Chief Executive Officer and Davender Sohi, Chief Financial Officer, will host the call and a question and answer period. The Company will report its financial results for the second quarter after the close of markets on Friday, August 14, 2020.

Conference Call Details

DATE:	August 17, 2020
TIME:	9:00 AM Eastern Time

CONFIRMATION #:	64751998

TORONTO:	416-764-8659
NORTH AMERICAN TOLL FREE:	1-888-664-6392
GERMANY TOLL FREE:	08007240293
COLOMBIA TOLL FREE:	018005184036

REPLAY TORONTO:	416-764-8677
REPLAY NORTH AMERICA:	1-888-390-0541
REPLAY ENTRY CODE:	751998#
REPLAY EXPIRATION DATE:	August 24, 2020

About Avicanna Inc.

Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions, estimates and assumptions of management in light of management’s experience and perception of historical trends, current conditions and expected developments at the date the statements are made, such as current and future market conditions, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated April 15, 2020 (the “AIF“) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

SOURCE Avicanna Inc.

Tags: cannabinoids, CSE, Marijuana, Medical Cannabis by Shoppers, Rho Phyto, stocks
Posted in All Recent Posts | Comments Off on Avicanna Inc. $AVCN.ca to Host Second Quarter 2020 Investor Conference Call $CRDL.ca $PCLO.ca $WEED.ca $ACB.ca

Terry Booth Schedules Investor Conference Call to Discuss Binovi’s $VISN.ca New Direction $EYPT $KALA

Posted by AGORACOM-JC at 4:16 PM on Friday, August 7th, 2020

http://www.smallcapepicenter.com/binovi%20square.png

Executive Chairman Terry Booth wishes to set up a special investor conference call to discuss the Company’s new direction
The call will be hosted on Tuesday, August 11^th, 2020 with Binovi Technologies Executive Chairman, Terry Booth and Adam Cegielski, CEO.

Toronto, New York – August 7, 2020 – Binovi Technologies Corp., (Binovi) (TSXV:VISN) | (OTC:BNVIF) announces that in light of the latest developments, Executive Chairman Terry Booth wishes to set up a special investor conference call to discuss the Company’s new direction. The call will be hosted on Tuesday, August 11^th, 2020 with Binovi Technologies Executive Chairman, Terry Booth and Adam Cegielski, CEO.

The call will be held on Tuesday August 11^th, at 4:15pm EST (1:15pm PST).

Conference details:

Canada/USA TF: 1-800-319-4610
International Toll: +1-604-638-5340
Germany TF: 0800-180-1954

Callers should dial in 5 – 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 5088

For additional information on the Company, please visit https://www.binovi.com/investor-reports/

About Binovi Technologies Corp.

Binovi is a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 1,500 locations across 20 countries.

Terry Booth

Executive Chairman

Adam Cegielski

Founder | CEO

Investor Relations

Email: [email protected]

Toll-free: 1 (844) 866-6162

https://www.binovi.com/investor-reports/

Forward looking information:

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Tags: Binovi Touch, CSE, Eli Wilson. Eye therapy, eye training, tsx
Posted in Binovi Technologies Corp. | Comments Off on Terry Booth Schedules Investor Conference Call to Discuss Binovi’s $VISN.ca New Direction $EYPT $KALA

Innocan’s $INNO.ca SHIR (TM) Beauty & Science #CBD Derma Cosmetics Products Passed Safety Assessments and Have Been Approved for Marketing in the European Union $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 4:45 PM on Thursday, August 6th, 2020

Announced that its SHIR™ CBD Derma Cosmetic product line, has successfully passed safety assessment in accordance with European Union (EU) cosmetic regulation No 1223/2009 and received a EU Cosmetic Product Safety Report for marketing in the European Union
SHIR™ skincare products combine the benefits of CBD with the most effective ingredients in an innovative formula to deliver visible results
The SHIR™ Beauty & science products that are approved for marketing in the Europe are: SHIR CBD+ ANTI-AGING Beauty Sleeping Mask ,SHIR CBD MUST Eye Serum, SHIR CBD MUST Recovery Lotion, SHIR CBD MUST Glow Oil, SHIR CBD MUST Face Cream, SHIR CBD+ ANTI-AGING Facial Serum

Herzliya, Israel and Calgary, Alberta–(August 6, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its SHIR™ CBD Derma Cosmetic product line, has successfully passed safety assessment in accordance with European Union (EU) cosmetic regulation No 1223/2009 and received a EU Cosmetic Product Safety Report for marketing in the European Union.

SHIR™ skincare products combine the benefits of CBD with the most effective ingredients in an innovative formula to deliver visible results. The SHIR™ Beauty & science products that are approved for marketing in the Europe are: SHIR CBD+ ANTI-AGING Beauty Sleeping Mask ,SHIR CBD MUST Eye Serum, SHIR CBD MUST Recovery Lotion, SHIR CBD MUST Glow Oil, SHIR CBD MUST Face Cream, SHIR CBD+ ANTI-AGING Facial Serum.

Innocan’s SHIR™ Beauty & Science CBD Derma Cosmetics

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/61225_6b37fecc040dc9bd_002full.jpg

“As a Pharma Company, Innocan is committed to creating premium products that meet the highest quality standards to provide consumer confidence,” Iris Bincovich, co-founder and CEO of Innocan states. “Compliance with EU regulation is a major milestone for us, following the receipt of technical validation from the FDA for the marketing in the US of our over-the-counter Relief & Go Pain Relief spray, a few weeks ago. The next step is to initiate our various distribution platforms to deliver our SHIR™ CBD Derma Cosmetic line across the European Union and other markets where legally permitted to do so.”

About Innocan

The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The Company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, the effectiveness and safety of the Company’s products, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: CBD, CBD Derma Cosmetics, CBD stocks, CSE, Innocan, Relief & Go Pain Relief Spray, SHIR, SHIR Skincare Products, stocks, tsx, tsx-v
Posted in Innocan Pharma Corporation | Comments Off on Innocan’s $INNO.ca SHIR (TM) Beauty & Science #CBD Derma Cosmetics Products Passed Safety Assessments and Have Been Approved for Marketing in the European Union $GWPH $CRDL.ca $PCLO.ca

VIDEO – ImagineAR $IP.ca $IPNFF Adds Media Powerhouse Michael Anderson To Spearhead UK & Euro Sales $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 4:30 PM on Thursday, August 6th, 2020

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

If you were a small cap Augmented Reality company from Vancouver that needed to appoint an old media / new media powerhouse to head up your European sales operations, we really don’t think you could have found someone better credentialed than Michael Anderson – and that’s exactly what ImagineAR (IP:CSE) (IPNFF:OTCQB) did.

Anderson is a highly regarded leader in the world of digital with his roots firmly based in UK media. Part entrepreneur, part corporate animal, he quickly rose through the ranks ending up as Managing Director of News UK. He worked for Rupert Murdoch and Les Hinton during his rise to the top and made the Board room of both News UK and Associated Newspapers (publishers of the Daily Mail).

Sensing the changing winds of the media business, Anderson was a driving force on the launch team of Metro, which overtook The Sun in 2018 as the largest circulation of any newspaper in the UK. At Metro, he was instrumental in the paper being cited as a new business case with commercial results not seen previously in the newspaper industry, growing revenue from £100k a week to £1m per week in just 12 months. Additionally, Mike was the founder of the Chelsea APPS Factory which included UK clients KPMG, Ladbrokes, Standard Life, TfL, Vanquis and Waitrose.

….. And now he is sensing another change in the winds to put his considerable talents and team behind the Augmented Reality solutions of ImagineAR.

If you don’t know what Augmented Reality (AR) is, this quote from Apple CEO Tim Cook is all the motivation you need to get up to speed:

“AR Will play an important role in how we use technology in the future – and promises to be as influential in our society as the smart phone”

Anderson wholeheartedly agrees, stating “ImagineAR is the most advanced AR platform in the market today and I am excited to launch the company’s sales and marketing initiatives in the UK and Europe.”

That quote is just the tip of the iceberg. Watch what Anderson has to say about the “unlimited possibilities of Augmented Reality” and some pretty good hints about whose doors he will be knocking on first …. which is pretty impressive given the fact August is vacation season in Europe 🙂

If our interview with CEO Alen Paul Silverrstieen and Michael Anderson is any indication, it sounds like the Company’s growth into the UK and Europe is all but assured in 2020 and well beyond.

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: AR, augmented reality, Chelsea APPS Factory, CSE, small cap, stocks, tsx, tsx-v
Posted in AGORACOM Via Satellite, Featured, Imagine AR | Comments Off on VIDEO – ImagineAR $IP.ca $IPNFF Adds Media Powerhouse Michael Anderson To Spearhead UK & Euro Sales $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Else Nutrition $BABY.ca Provides Corporate Update $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 1:02 PM on Thursday, August 6th, 2020

http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Company’s proprietary, plant based, clean label formula for toddlers will launch in August 2020
A full-scale marketing campaign for the launch has commenced with samples and pre-order sales over the past few weeks; the product will be shipped to consumers in the U.S. and Canada from two U.S. based warehouses of a third-party logistics partner
The Company’s Amazon.com store will launch in the coming weeks

VANCOUVER, BC /August 6, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company“), a developer of plant-based alternatives to dairy-based baby nutrition, is pleased to provide the following corporate update.

“Our team has been working relentlessly, during an unprecedently difficult time, to bring our product to market. As we get set to launch, we are beyond thrilled to have crossed major hurdles over the past months and weeks – including full scale manufacturing with a U.S. based partner and mobilization of our U.S. supply chain which has culminated in our ability to ship samples of our plant-based formula for toddlers to eager parents across North America,” said Ms. Hamutal Yitzhak, CEO and Co-Founder of Else.

North America Launch

The Company’s proprietary, plant based, clean label formula for toddlers will launch in August 2020. A full-scale marketing campaign for the launch has commenced with samples and pre-order sales over the past few weeks; the product will be shipped to consumers in the U.S. and Canada from two U.S. based warehouses of a third-party logistics partner. The Company’s Amazon.com store will launch in the coming weeks.

U.S. Manufacturing

The first full-scale commercial manufacturing run of the toddler nutrition powder product was successfully completed by the Company’s U.S. manufacturing partner and packed at a co-packer plant in Nevada.

The terms of the U.S. manufacturing agreement have been negotiated and a formal agreement will be executed upon the receipt of final yield and cost optimization parameters. The next commercial manufacturing run is booked and secured.

FDA Regulatory Pathway

The Company in conjunction with its FDA consulting partner continues to progress on the regulatory pathway for multiple products including an infant formula and new products currently in development for the adult nutrition market.

Health and Happiness International Holdings Limited

The Company’s negotiations with its strategic partner, H&H Global, for distribution rights of the toddler and infant formula in France are advancing well. The parties are studying the target market needs, channels, and regulations, in addition to preparing a launch plan and negotiating the distribution terms. Additionally, discussions regarding distribution in additional markets have also commenced.

Cash and Runway

The company is well capitalized, with approximately CAD$7.0 million in cash, and no short or long-term debt, to fully support its manufacturing and go-to-market plans for the next 12 months.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

For more information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director of Else Nutrition
Email: [email protected]
Telephone: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will”, “expect” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that listing on the FSE will create additional liquidity and attract additional investors in the European market. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Tags: baby food, CSE, investing, organic, small cap, stocks, tsx, tsx-v
Posted in Else Nutrition Holdings Inc., Featured | Comments Off on Else Nutrition $BABY.ca Provides Corporate Update $KMB $BMY $ABT $WYE

VIDEO – Kontrol Energy $KNR.ca Technology Could Detect #COVID19 In Big Buildings Through Real-Time Air Sampling & Alerts $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 10:14 AM on Thursday, August 6th, 2020

If Google NEST is the leader in smart home technology, then Kontrol Energy (KNR:CSE) is the small cap equivalent for smart building technology. More than just lip service, their established Blue Chip customer base includes:

Beyond Meat
Oxford Properties
Brookfield Asset Management
Telus
Suncor Energy
….. Many More

Moreover, they’ve signed a major deal wth Toyota (Tsusho Canada), targeting 200 plants requiring up to $1 million each in automation retrofits.

CONCLUSION? When Kontrol Energy says they are entering a 4-week testing phase – with an independent lab – to determine if their technology can detect COVID-19 in the air of big buildings, you need to take the news seriously. You know who else took it seriously? The National Research Council, who granted Kontrol $50,000 to conduct the test. The amount may seem small but that’s because KNR has already done most of the leg work already and is now in the final 4-week testing phase.

If successful, the implications could be enormous for their Tier-1 client base, as well as, all commercial buildings, government buildings, schools and other big essential locations that need to find a way to start bringing people back. In short, Kontrol Energy’s BioCloud Analyzer could have a major impact on the North American economy.